Shuttle Pharmaceuticals is trading at $3.11 (-5.18%) in pre-market, continuing its downward trajectory following Thursday’s sharp selloff.
- The decline is attributed to recent insider sales by HRT Financial and dilution concerns stemming from the company’s merger with United Dogecoin.
- Investors are weighing the impact of convertible preferred stock and a planned reverse stock split, which have heightened negative sentiment.
- With no new company announcements overnight, the move reflects ongoing event-driven volatility and a lack of fresh positive catalysts.